Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, will release its second quarter 2024 financial results on Wednesday, August 7, 2024, after the Nasdaq Global Market closes. The company will host a conference call at 4:30 p.m. E.T. to discuss the results. Investors can access the webcast live on Sarepta's website, with a replay available for one year. Phone participants must register online to receive dial-in details.
Sarepta focuses on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), with over 40 programs in various stages of development. The company's pipeline is driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.
Sarepta Therapeutics (NASDAQ:SRPT), un leader nella medicina genetica di precisione per malattie rare, pubblicherà i suoi risultati finanziari del secondo trimestre 2024 mercoledì 7 agosto 2024, dopo la chiusura del Nasdaq Global Market. L'azienda organizzerà una conference call alle 16:30 E.T. per discutere i risultati. Gli investitori possono accedere alla webconferenza in diretta sul sito di Sarepta, con una riproduzione disponibile per un anno. I partecipanti telefonici devono registrarsi online per ricevere i dettagli per la chiamata.
Sarepta si concentra sullo sviluppo di trattamenti per la distrofia muscolare di Duchenne (DMD) e le distrofie muscolari delle cinture (LGMD), con oltre 40 programmi in varie fasi di sviluppo. Il portafoglio dell'azienda è guidato dal suo motore di medicina genetica di precisione multi-piattaforma in terapia genica, RNA e editing genetico.
Sarepta Therapeutics (NASDAQ:SRPT), líder en medicina genética de precisión para enfermedades raras, publicará sus resultados financieros del segundo trimestre de 2024 el miércoles 7 de agosto de 2024, después del cierre del Nasdaq Global Market. La compañía realizará una conferencia telefónica a las 4:30 p.m. E.T. para discutir los resultados. Los inversores pueden acceder a la transmisión en vivo en el sitio web de Sarepta, con una repetición disponible durante un año. Los participantes por teléfono deben registrarse en línea para recibir los detalles de la llamada.
Sarepta se centra en desarrollar tratamientos para la distrofia muscular de Duchenne (DMD) y las distrofias musculares de cinturón (LGMD), con más de 40 programas en varias etapas de desarrollo. La cartera de la compañía está impulsada por su motor de Medicina Genética de Precisión de múltiples plataformas en terapia génica, ARN y edición genética.
Sarepta Therapeutics (NASDAQ:SRPT)는 희귀 질병을 위한 정밀 유전 의학의 선두주자로, 2024년 2분기 재무 결과를 2024년 8월 7일 수요일에 나스닥 글로벌 마켓이 마감된 후 발표할 예정입니다. 회사는 오후 4시 30분 E.T.에 결과를 논의하기 위한 컨퍼런스 콜을 개최합니다. 투자자들은 Sarepta 웹사이트에서 생중계 웹캐스트에 접속할 수 있으며, 1년 동안 다시 볼 수 있습니다. 전화 참여자는 다이얼 인 세부정보를 받기 위해 온라인으로 등록해야 합니다.
Sarepta는 뒤셴 근육 디스트로피(DMD) 및 사지 띠 근육 디스트로피(LGMD)에 대한 치료법 개발에 집중하고 있으며, 40개 이상의 프로그램이 다양한 개발 단계에 있습니다. 회사의 파이프라인은 유전자 치료, RNA 및 유전자 편집에서 다중 플랫폼 정밀 유전 의학 엔진에 의해 추진됩니다.
Sarepta Therapeutics (NASDAQ:SRPT), un leader dans le domaine de la médecine génétique de précision pour les maladies rares, publiera ses résultats financiers du deuxième trimestre 2024 le mercredi 7 août 2024, après la clôture du Nasdaq Global Market. La société organisera une conférence téléphonique à 16h30 E.T. pour discuter des résultats. Les investisseurs peuvent accéder à la webdiffusion en direct sur le site de Sarepta, avec un replay disponible pendant un an. Les participants par téléphone doivent s'inscrire en ligne pour recevoir les informations de connexion.
Sarepta se concentre sur le développement de traitements pour la dystrophie musculaire de Duchenne (DMD) et les dystrophies musculaires du ceinturons (LGMD), avec plus de 40 programmes à différents stades de développement. Le pipeline de l'entreprise est propulsé par son moteur de Médecine Génétique de Précision multi-plateformes en thérapie génique, ARN et édition génétique.
Sarepta Therapeutics (NASDAQ:SRPT), ein führendes Unternehmen im Bereich der präzisen genetischen Medizin für seltene Krankheiten, wird seine finanziellen Ergebnisse für das zweite Quartal 2024 am Mittwoch, den 7. August 2024, nach dem Schließen des Nasdaq Global Market veröffentlichen. Das Unternehmen wird um 16:30 Uhr E.T. eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können die Webkonferenz live auf der Website von Sarepta ansehen, mit einer Wiederholung, die ein Jahr lang verfügbar ist. Telefonteilnehmer müssen sich online registrieren, um die Einwahldetails zu erhalten.
Sarepta konzentriert sich auf die Entwicklung von Behandlungen für die Duchenne-Muskeldystrophie (DMD) und die Hüftgürteldystrophien (LGMD), mit über 40 Programmen in verschiedenen Entwicklungsstadien. Die Pipeline des Unternehmens wird von seiner Multi-Plattform-Präzisionsgenetik-Motor in der Gentherapie, RNA und Gen-Editing vorangetrieben.
- Leadership position in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs)
- Over 40 programs in various stages of development
- Multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing
- None.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729073260/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
FAQ
When will Sarepta Therapeutics (SRPT) report its Q2 2024 financial results?
What time is Sarepta Therapeutics' (SRPT) Q2 2024 earnings conference call?
How can investors access Sarepta Therapeutics' (SRPT) Q2 2024 earnings call?
What are the main focus areas of Sarepta Therapeutics (SRPT)?
